Should I buy or sell Bionomics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNOX shares. View BNOX analyst ratings or view top-rated stocks .

What is Bionomics' stock price target for 2024?

2 Wall Street research analysts have issued 1 year price objectives for Bionomics' stock. Their BNOX share price targets range from $8.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 814.6% from the stock's current price. View analysts price targets for BNOX or view top-rated stocks among Wall Street analysts .

How have BNOX shares performed in 2024?

Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX stock has decreased by 33.5% and is now trading at $0.9840. View the best growth stocks for 2024 here .

Are investors shorting Bionomics?

Bionomics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 258,400 shares, an increase of 344.0% from the March 15th total of 58,200 shares. Based on an average daily trading volume, of 213,800 shares, the days-to-cover ratio is currently 1.2 days. View Bionomics' Short Interest .

When did Bionomics IPO?

Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at $12.35 per share.

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BNOX

Bionomics (BNOX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BNOX Stock Alerts

$0.98

+0.02 (+2.60%)

(As of 01:30 PM ET)

Compare

Today's Range: $0.96
▼
$1.00
50-Day Range: $0.92
▼
$1.30
52-Week Range: $0.87
▼
$6.41

Volume: 16,210 shs
Average Volume: 203,114 shs
Market Capitalization: $8.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Bionomics alerts:

Bionomics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 814.6% Upside
$9.00 Price Target
Short Interest: Healthy
3.17% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.59) to ($4.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Bionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bionomics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.17% of the outstanding shares of Bionomics have been sold short.
Short Interest Ratio / Days to Cover
Bionomics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bionomics has recently increased by 343.99%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Bionomics does not currently pay a dividend.
Dividend Growth
Bionomics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNOX.

0.9

News and Social Media Coverage

News Sentiment
Bionomics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Bionomics this week, compared to 0 articles on an average week.
Search Interest
Only 7 people have searched for BNOX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bionomics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.50% of the stock of Bionomics is held by insiders.
Percentage Held by Institutions
Only 15.90% of the stock of Bionomics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bionomics are expected to decrease in the coming year, from ($2.59) to ($4.17) per share.
Price to Book Value per Share Ratio
Bionomics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Bionomics Stock (NASDAQ:BNOX)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNOX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BNOX Stock News Headlines

April 17, 2024 | finance.yahoo.com

Bionomics Limited (BNOX) Stock Historical Prices & Data - Yahoo Finance

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study Results

April 18, 2024 | GoldenCrest Metals (Ad)

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

March 21, 2024 | msn.com

Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars

March 21, 2024 | globenewswire.com

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

March 20, 2024 | finance.yahoo.com

Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)

February 22, 2024 | globenewswire.com

Bionomics to Present at the 2024 BIO CEO & Investor Conference

February 22, 2024 | benzinga.com

Bionomics Stock (NASDAQ:BNOX), Short Interest Report

April 18, 2024 | GoldenCrest Metals (Ad)

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

January 22, 2024 | finanznachrichten.de

Bionomics Ltd: Bionomics Provides a Review of 2023 and of 2024 Plans

January 22, 2024 | finance.yahoo.com

Bionomics Provides a Review of 2023 and of 2024 Plans

December 7, 2023 | morningstar.com

Bionomics Ltd ADR BNOX

December 6, 2023 | finance.yahoo.com

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

December 4, 2023 | ca.finance.yahoo.com

Bionomics Limited (BNOX)

October 19, 2023 | benzinga.com

Bionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3

October 3, 2023 | markets.businessinsider.com

Promising Progress of BNC210 Bolsters Buy Rating on Bionomics Amidst Rising Interest in SAD Treatments

September 30, 2023 | finance.yahoo.com

Bionomics Full Year 2023 Earnings: AU$3.60 loss per share (vs AU$0.016 loss in FY 2022)

September 29, 2023 | finance.yahoo.com

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

September 29, 2023 | msn.com

Bionomics’ stock rallies 300% after company reports positive results in trial of PTSD treatment

September 28, 2023 | markets.businessinsider.com

Bionomics' Victory - Analysts Note Optimism Around Promising Prospects for PTSD Treatment

September 28, 2023 | finance.yahoo.com

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

September 28, 2023 | msn.com

Why Is Stress Disorder Focused Bionomics Stock Trading Higher Today?

September 28, 2023 | investorplace.com

Why Is Bionomics (BNOX) Stock Up 347% Today?

September 4, 2023 | nasdaq.com

Bionomics Limited American Depository Shares (BNOX)

July 31, 2023 | finanznachrichten.de

Bionomics Ltd: Quarterly Activities and Cashflow Report

June 15, 2023 | finance.yahoo.com

Bionomics to Present at Upcoming June Investor Conferences

May 30, 2023 | finance.yahoo.com

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

See More Headlines

Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BNOX
CUSIP: N/A
CIK: 1191070
Web: www.bionomics.com.au
Phone: 088-150-7400
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $10.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +838.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 3.81
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 782.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.73 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 8,160,000
Free Float: 8,038,000
Market Cap: $7.83 million
Optionable: Not Optionable
Beta: -0.09

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Spyridon Papapetropoulos M.D. (Age 51)
Ph.D., CEO, President & Director
Comp: $498.92k
Mr. Adrian Hinton BEC (Age 71)
F.C.A., Financial Controller
Comp: $193.97k
Mr. Timothy M. Cunningham CPA (Age 61)
M.B.A., Chief Financial Officer
Prof. Paul Rolan D.C.P.S.A.
F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
Dr. Julie Kerner Ph.D.
Senior Vice President of Business Operations
Ms. Suzanne Irwin B.Com.
FCIS, Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

Point72 Asset Management L.P.
Sold 330,626 shares on 2/14/2024
Ownership: 4.056%

View All Institutional Transactions

BNOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Bionomics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNOX shares.
View BNOX analyst ratings or view top-rated stocks.
What is Bionomics' stock price target for 2024?: 2 Wall Street research analysts have issued 1 year price objectives for Bionomics' stock. Their BNOX share price targets range from $8.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 814.6% from the stock's current price.
View analysts price targets for BNOX or view top-rated stocks among Wall Street analysts.
How have BNOX shares performed in 2024?: Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX stock has decreased by 33.5% and is now trading at $0.9840.
View the best growth stocks for 2024 here.
Are investors shorting Bionomics?: Bionomics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 258,400 shares, an increase of 344.0% from the March 15th total of 58,200 shares. Based on an average daily trading volume, of 213,800 shares, the days-to-cover ratio is currently 1.2 days.
View Bionomics' Short Interest.

When did Bionomics IPO?: Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at $12.35 per share.
How do I buy shares of Bionomics?: Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNOX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial